High-dose atorvastatin causes regression of endometriotic implants: a rat model
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This prospective randomized-controlled animal study was designed to determine the effects of atorvastatin on experimentally induced endometriosis in a rat model. METHODS: Thirty-seven Wistar-Albino rats in which endometriotic implants were induced were randomly divided into four groups. Group I (Low-dose atorvastatin group, eight rats) were given 0.5 mg kg(-1) day(-1) oral atorvastatin. Group II (High-dose atorvastatin group, 10 rats) were given 2.5 mg kg(-1) day(-1) oral atorvastatin. Group III were given a single dose of 1 mg kg(-1) s.c. leuprolide acetate (GnRH agonist group, nine rats). Group IV were given no medication and served as controls (10 rats). All rats received the treatment for 21 days and were then euthanized to assess the implants' size, vascular endothelial growth factor (VEGF) level in peritoneal fluid and histological score. RESULTS: At the end of the treatment, the mean areas of implants were smaller and VEGF levels in peritoneal fluid were lower in Groups II and III than those in Group I and the control group (all P < 0.05). The mean areas of implants decreased from 41.2 +/- 13.9 to 22.7 +/- 13.9 mm(2) after medication in Group II and decreased from 41.2 +/- 18.1 to 13.1 +/- 13.8 mm(2) in Group III (both P < 0.05), whereas in Group I, the mean area increased from 43.0 +/- 12.7 to 50.5 +/- 13.9 mm(2) (P < 0.05). CONCLUSIONS: High-dose atorvastatin caused a significant regression of endometriotic implants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
ESHRE guideline for the diagnosis and treatment of endometriosis
Kennedy, S., Bergqvist, A., Chapron, C., D’Hooghe, T., Dunselman, G., Greb, R., Hummelshoj, L., Prentice, A., & Saridogan, E. (2005) · Human Reproduction · doi:10.1093/humrep/dei135 · Cited by 1,584 · cited 2×
“Endometriosis is defined as the presence of endometrial tissue, consisting of both glandular epithelium and stroma, outside the uterine cavity (Kennedy et al., 2005).”
BackgroundCilla, D. D., Whitfield, L. R., Gibson, D. M., Sedman, A. J., & Posvar, E. L. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90218-0 · Cited by 204 · cited 2×
“2 mmol l(21) for atorvastatin (10–80 mg day(21)) (Cilla et al., 1996).”
BackgroundInfluential
Cited by
Chronic pelvic pain and endometriosis: translational evidence of the relationship and implications
Stratton, P., & Berkley, K. J. (2011) · Human Reproduction Update · doi:10.1093/humupd/dmq050 · Cited by 442
New developments in the medical treatment of endometriosis
Bedaiwy, M. A., Alfaraj, S., Yong, P., & Casper, R. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.12.025 · Cited by 176
New trends for the medical treatment of endometriosis
Rocha, A. L. L., Reis, F. M., & Petraglia, F. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.683783 · Cited by 60
A peek into the drug development scenario of endometriosis – A systematic review
Goenka, L., George, M., & Sen, M. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.03.092 · Cited by 37
Therapeutic Roles of Statins in Gynecology and Obstetrics: The Current Evidence
Zeybek, B., Costantine, M., Kilic, G. S., & Borahay, M. A. (2018) · Reproductive Sciences · doi:10.1177/1933719117750751 · Cited by 31
New drugs in development for the treatment of endometriosis
Fedele, L., Somigliana, E., Frontino, G., Benaglia, L., & Vigano, P. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.8.1187 · Cited by 30
“Other antiangiogenic agents such as endostatin, TNP-470, 2-methoxyestradiol, atorvastatin and anginex are also able to inhibit the development and growth of endometriosis in animals [74,75,77-80] .”
BackgroundCould statins constitute a novel treatment for endometriosis? Systematic review of the literature
Gibran, L., Maranhão, R. C., Abrão, M. S., Baracat, E. C., & Podgaec, S. (2014) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2014.05.028 · Cited by 29
Metadata
- Authors
- Oktem, M., Esinler, I., Eroglu, D., Haberal, N., Bayraktar, N., & Zeyneloglu, H. B.
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-01-18
- Volume
- 22
- Issue
- 5
- Pages
- 1474-1480
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2117630250
- Cited by
- 87
- References
- 3
- FWCI
- 6.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.